Skip to main content
  • Explore Research
  • Learn About Clinical Trials
  • Pediatric Clinical Trials
  • Clinical Trial Video Series
  • Featured Research
  • Find a Clinical Trial
  • Clinical Trial Patient Stories
  • Get Involved
  • Research Updates
  • Resources for Professionals
  • Newsletter Archives
  • Talk to a Specialist

Featured Research

The Crohn's & Colitis Foundation collaborates with academic and industry researchers to help enroll patients with Crohn’s disease and ulcerative colitis into clinical studies. The list below highlights our partners' current research studies. Please note that these partners have paid to have their trials posted below, and the Crohn's & Colitis Foundation does not endorse any particular study.

For a comprehensive listing of all research studies currently recruiting, please visit our IBD Clinical Trial Finder.

Clinical Trials Phases
  • (X) Phase 2 (17)

Current Results: 17 entries

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Efficacy, and Biomarker Response of BMS-986165 in Subjects with Moderate to Severe Ulcerative Colitis
Phase 2
Sponsor: Bristol-Myers Squibb
Description:

The purpose of the study is to evaluate the safety and effectiveness of the study medicine in adults with ulcerative colitis.

Recruiting Now »
Multicenter, randomized, double-blind, placebo-controlled phase II clinical trial to evaluate the effectiveness and safety of CBP-307 in subjects with moderate to severe ulcerative colitis (UC)
Phase 2
Sponsor: Suzhou Connect Biopharmaceuticals, Ltd.
Description:

Primary objective: To compare clinical efficacy by evaluating the clinical response to CBP-307 (P.O. for 12 consecutive weeks) versus placebo in subjects with moderate to severe UC

Recruiting Now »
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate GB004 In Adult Subjects with Mild-To-Moderate Active Ulcerative Colitis. (SHIFT-UC Study)
Phase 2
Sponsor: GB004, Inc. (a subsidiary of Gossamer Bio)
Description:

Primary Objective: To Evaluate the Effect of GB004 Compared to Placebo on Clinical Remission

Recruiting Now »
Lattice Study for Ulcerative Colitis (LATTICE-UC): A Phase 2 Randomized, Double-Blind, Placebo- Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects with Moderate to Severe Ulcerative Colitis
Phase 2
Sponsor: Bristol-Myers Squibb
Description:

The purpose of the LATTICE-UC is to evaluate how well the oral investigational drug (called BMS- 986165) works and how safe it is for patients with moderately to severely active ulcerative colitis.

Recruiting Now »
Lattice Study for Crohn’s Disease (LATTICE-CD): A Phase 2 Randomized, Double-Blind, Placebo- Controlled Study of the Safety and Efficacy of BMS 986165 in Participants with Moderate to Severe Crohn's Disease
Phase 2
Sponsor: Bristol-Myers Squibb
Description:

The purpose of the LATTICE-CD is to evaluate how well an oral investigational drug (called BMS- 986165) works and how safe it is for patients with moderately to severely active Crohn’s disease.

Recruiting Now »
A Phase 2 Multi-Center, Randomized, Double-Blind, Placebo˗Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Induction Therapy with 2 Doses of TD-1473 in Patients with Moderately-to-Severely Active Crohn’s Disease
Phase 2
Sponsor: Theravance Biopharma Ireland Limited
Description:

To assess the change in symptoms and overall safety of TD-1473, which is an investigational product, in moderately-to-severely active Crohn's disease.

Recruiting Now »
A study to evaluate the efficacy and safety of PF-06480605 in adult participants with moderate to severe ulcerative colitis (TUSCANY 2)
Phase 2
Sponsor: Pfizer NCT04090411
Description:
  • To evaluate the efficacy of PF-06480605 in induction of clinical remission at Week 14 in participants with moderate to severe active UC.
  • To evaluate the safety and tolerability of PF-06480605 during the chronic therapy period (from Week 14 to the End of Study Visit) in participants with moderate to severe active UC during the chronic therapy period.
Recruiting Now »
VEGA: A Study of the efficacy and safety of combination study medicine in adults with Ulcerative Colitis
Phase 2
Sponsor: Janssen Vega
Description:

The VEGA study is evaluating the safety and effectiveness of the study medicine in adults with ulcerative colitis (UC).

Recruiting Now »
ECO-RESET: A Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Multicenter Study to Assess Efficacy and Safety of SER-287 in Adults with Active Mild-to-Moderate Ulcerative Colitis
Phase 2
Sponsor: Seres Therapeutics
Description:

To demonstrate the efficacy of SER-287, after 10 weeks of induction dosing (following vancomycin pre-treatment), in achieving clinical remission.

Recruiting Now »
A 54-Week Treatment, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo and Active-Controlled (Entyvio), Parallel-Group Phase 2 Study to Assess the Efficacy and Safety of A Study Drug in Participants with Moderately to Severely Active UC...
Phase 2
Sponsor: Allergan
Description:

Full Study Title: A 54-Week Treatment, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo and Active-Controlled (Entyvio), Parallel-Group Phase 2 Study to Assess the Efficacy and Safety of A Study Drug in Participants with Moderately to Severely Active Ulcerative Colitis [Expedition]

The primary objective of this study is to evaluate the efficacy and safety of a study drug versus placebo in patients with moderately to severely active Ulcerative Colitis.

Recruiting Now »

Pagination

  • Current page 1
  • Page 2
  • Next page ››
  • Last page Last »
If you are interested in listing your trial on the Featured Research page, please contact [email protected]

Browser not supported

Your Internet Explorer is outdated. For optimal security settings and a better experience on our site, try switching to one of these options:

Google Chrome

Download Chrome

Firefox

Download Firefox

Safari (macOS 10.8+ only)

Download Safari